Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Eirgen Pharma Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 2 art units, so the portfolio has separate examination assignments.
CHANG, KYUNG SOOK is the busiest examiner, with 1 pending matter. Counsel should maintain matter-specific responses while checking both assignments for related prior-art or claim-scope issues that could support a consistent portfolio position.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18903677 | PEDIATRIC DOSAGE FORMS, METHODS OF MAKING AND USING | CHANG, KYUNG SOOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005946 | HARD CAPSULE DOSAGE FORM AND USES THEREOF | PALENIK, JEFFREY T | 84d overdue |
| 18903677 | PEDIATRIC DOSAGE FORMS, METHODS OF MAKING AND USING | CHANG, KYUNG SOOK | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18903677 | PEDIATRIC DOSAGE FORMS, METHODS OF MAKING AND USING | CHANG, KYUNG SOOK | 1613 | §103§112Other | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18005946 | HARD CAPSULE DOSAGE FORM AND USES THEREOF | PALENIK, JEFFREY T | 1615 | §103DP | Non-Final OA | 84d overdue | Pending | Jan 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEirgen Pharma Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kyung Sook Chang has the most, with 1 of Eirgen Pharma Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
